Radiation Therapy News and Research

RSS

Radiation therapy (also called radiotherapy, x-ray therapy, or irradiation) is the use of a certain type of energy (called ionizing radiation) to kill cancer cells and shrink tumors. Radiation therapy injures or destroys cells in the area being treated (the “target tissue”) by damaging their genetic material, making it impossible for these cells to continue to grow and divide. Although radiation damages both cancer cells and normal cells, most normal cells can recover from the effects of radiation and function properly. The goal of radiation therapy is to damage as many cancer cells as possible, while limiting harm to nearby healthy tissue.

Treatment of pelvic nodes can be easily integrated into IMRT-based treatment strategy

Treatment of pelvic nodes individualized by inclusion of sentinel nodes can be easily integrated into an IMRT-based treatment strategy, according to the new study conducted by a group of researchers from T-bingen and Munich in Germany. The target volume concept seems to correctly cover individual pelvic nodes, which is indicated by the absence of any nodal recurrence within five years of follow-up.

18 Nov 2013

Quantitative models predict risk of acute urinary symptoms in prostate cancer patients treated with RT

An interim study by Italian researchers showed that using a modelling programme together with IPSS and dosage measure can predict the severity of acute urinary symptoms in patients with early prostate cancer who underwent radiotherapy.

16 Nov 2013

Bleach solution could provide new way to treat skin damage

Processes that age and damage skin are impeded by dilute bleach solution, according to a new study by researchers at the Stanford University School of Medicine.

16 Nov 2013

Alliance HealthCare Services third quarter 2013 revenue decreases $2.6 million

Alliance HealthCare Services, Inc., a leading national provider of outpatient diagnostic imaging and radiation therapy services, announced results for the third quarter ended September 30, 2013.

6 Nov 2013

Advanced prostate cancer therapies: an interview with Dr. Nancy Dawson, Lombardi Comprehensive Cancer Center

The prostate gland produces part of the seminal fluid that protects sperm. It is located in front of the rectum and under the bladder, and surrounds the urethra, the tube through which urine flows from the bladder to and out of the penis.

6 Nov 2013

Physicians' Education Resource to host 11th Annual School of Breast Oncology in Atlanta, GA

The go-to source for excellence in continuing medical education, Physicians' Education Resource®, LLC, will host the 11th Annual School of Breast Oncology November 7-10 at the Emory University Conference Center in Atlanta, GA.

6 Nov 2013

The Princess Margaret Cancer Foundation launches innovative Fall advertising campaign

The Princess Margaret Cancer Foundation launches an innovative Fall advertising campaign this month which focuses on the extraordinary team of 63 surgeons, all of whom who are integral reasons why the Princess Margaret Cancer Centre is one of the top 5 cancer research centres in the world.

5 Nov 2013

RaySearch Laboratories, Hitachi sign long-term distribution agreement

RaySearch Laboratories AB has entered into a long-term distribution agreement with Hitachi Medical Corporation based in Tokyo, Japan. The agreement means that Hitachi will be fully responsible for marketing, sales and service of RaySearch's proprietary treatment planning system RayStation® on the Japanese market from April 1, 2014.

4 Nov 2013

Multidisciplinary care critically important for prostate cancer patients

Only half of the men who receive a prostate cancer diagnosis in North Carolina consult with more than one type of physician before deciding on a course of treatment, according to research presented by University of North Carolina researchers at the 2013 American Society for Radiation Oncology annual meeting on Sept. 24.

31 Oct 2013

Men treated by self-referring urologists more likely to undergo unnecessary IMRT

A comprehensive review of Medicare claims for more than 45,000 patients from 2005 through 2010 found that nearly all of the 146 percent increase in intensity-modulated radiation therapy (IMRT) for prostate cancer among urologists with an ownership interest in the treatment was due to self-referral, according to new research, "Urologists' Use of Intensity-Modulated Radiation Therapy for Prostate Cancer," released today in The New England Journal of Medicine (NEJM) for its October 24, 2013 issue.

25 Oct 2013

Use of IMRT for prostate cancer doubles when self-referral's financial incentives involved

A comprehensive review of Medicare claims for more than 45,000 patients from 2005 through 2010 found that nearly all of the 146 percent increase in intensity-modulated radiation therapy for prostate cancer among urologists with an ownership interest in the treatment was due to self-referral, according to new research, "Urologists' Use of Intensity-Modulated Radiation Therapy for Prostate Cancer," released today in The New England Journal of Medicine for its October 24, 2013 issue.

25 Oct 2013

Temple University surgeons use CVHP Scalpel to remove inoperable metastatic Stage 4 Breast cancer

On September 18, 2013, a surgical team at Temple University Hospital, Philadelphia, Pa., performed a groundbreaking procedure on a patient who had previously been diagnosed with inoperable metastatic Stage 4 Breast cancer, using the Canady Vieira Hybrid Plasma Scalpel developed and sold by US Medical Innovations, LLC.

25 Oct 2013

HM Hospitales expects to treat first patients with Elekta's Versa HD system in 2015

HM Hospitales, a private hospital group in Spain, anticipates treating its first patients with Elekta's Versa HD™ system in 2015. Versa HD, to be sited in the group's sixth hospital, is an advanced radiation treatment system designed to enhance the management of cancer care and treat a broad spectrum of tumors throughout the body.

From Elekta 24 Oct 2013

Metformin could serve as radiosensitizer to treat patients with stage III non-small cell lung cancer

Treating aggressive lung cancer with the diabetes drug metformin along with radiation and chemotherapy may slow tumor growth and recurrence, suggests new preliminary findings from researchers at the Perelman School of Medicine at the University of Pennsylvania being presented during an oral abstract session October 28 at the 15th World Conference on Lung Cancer.

24 Oct 2013

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

The nanopharmaceutical drug CRLX101 is showing promise as a potential new treatment for cancers that develop resistance to antiangiogenic drugs and radiation therapy, according to clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23.

22 Oct 2013

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation , today announced the results of the MPACT phase III clinical trial of ABRAXANE® in combination with gemcitabine were published online in the October 16th edition of the New England Journal of Medicine.

17 Oct 2013

Common catalyst cerium oxide opens door to nanochemistry for medicine

Scientists at Rice University are enhancing the natural antioxidant properties of an element found in a car's catalytic converter to make it useful for medical applications.

16 Oct 2013

Crown Bioscience enters into collaboration with Xstrahl for radiation biology research

Crown Bioscience, Inc., a leading global drug discovery and development service company, today announces that it has entered into a collaboration with Xstrahl Ltd, a leading designer and manufacturer of X-Ray solutions for radiation biology research.

From Xstrahl 15 Oct 2013

DIM compound derived from cruciferous vegetable protects rodents from radiation doses

Georgetown University Medical Center researchers say a compound derived from cruciferous vegetable such as cabbage, cauliflower and broccoli protected rats and mice from lethal doses of radiation.

15 Oct 2013

FDA approves OTREXUP injection for adults with RA, children with active pJIA

Antares Pharma, Inc. today announced the approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration. OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.

14 Oct 2013

Radiation Therapy News and Research

Further Reading

Treatment of pelvic nodes can be easily integrated into IMRT-based treatment strategy

Quantitative models predict risk of acute urinary symptoms in prostate cancer patients treated with RT

Bleach solution could provide new way to treat skin damage

Alliance HealthCare Services third quarter 2013 revenue decreases $2.6 million

Advanced prostate cancer therapies: an interview with Dr. Nancy Dawson, Lombardi Comprehensive Cancer Center

Physicians' Education Resource to host 11th Annual School of Breast Oncology in Atlanta, GA

The Princess Margaret Cancer Foundation launches innovative Fall advertising campaign

RaySearch Laboratories, Hitachi sign long-term distribution agreement

Multidisciplinary care critically important for prostate cancer patients

Men treated by self-referring urologists more likely to undergo unnecessary IMRT

Use of IMRT for prostate cancer doubles when self-referral's financial incentives involved

Temple University surgeons use CVHP Scalpel to remove inoperable metastatic Stage 4 Breast cancer

HM Hospitales expects to treat first patients with Elekta's Versa HD system in 2015

Metformin could serve as radiosensitizer to treat patients with stage III non-small cell lung cancer

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Common catalyst cerium oxide opens door to nanochemistry for medicine

Crown Bioscience enters into collaboration with Xstrahl for radiation biology research

DIM compound derived from cruciferous vegetable protects rodents from radiation doses

FDA approves OTREXUP injection for adults with RA, children with active pJIA

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News